Conformational study of a series of somatostatin analogues with antitumor and/or GH inhibitory activity.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  International journal of peptide & protein research

• Publication date

  2009-01-12

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1111/J.1399-3011.1994.TB00390.XPMID 7911792
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Novel somatostatin analogs with tyrosine kinase inhibitory and antitumor activity.

  1993cited by this paper
• Conformational study of somatostatin analogues in methanol at low temperature

  1991cited by this paper
• Conformational study of a somatostatin analogue in DMSO/water by 2D NMR.

  1990cited by this paper
• Conformational study of super-active analogues of somatostatin with reduced ring size by XXXH nmr

  1988cited by this paper
• Secretion of somatostatin and its physiologic function.

  1987cited by this paper
• MLEV-17-based two-dimensional homonuclear magnetization transfer spectroscopy

  1985cited by this paper
• Octapeptide analogs of somatostatin exhibiting greatly enhanced in vivo and in vitro inhibition of growth hormone secretion in the rat.

  1985cited by this paper
• SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action.

  1982cited by this paper
• Two-dimensional chemical exchange and cross-relaxation spectroscopy of coupled nuclear spins

  1981cited by this paper

• Molecular insights into amyloid toxicity using model lipid membranes

  2019cites this paper
• Three-dimensional consensus structure of sst2-selective somatostatin (SRIF) antagonists by NMR.

  2008cites this paper
• Evaluation of the antitumor efficacy of the somatostatin structural derivative TT-232 on different tumor models.

  2006cites this paper
• Structure-activity relationship studies optimizing the antiproliferative activity of novel cyclic somatostatin analogues containing a restrained cyclic beta-amino acid.

  2005cites this paper
• TT-232: An Anti-tumour and Anti-inflammatory Peptide Therapeutic in Clinical Development

  2005cites this paper
• Binding crevice for TT-232 in a homology model of type 1 somatostatin receptor.

  2004cites this paper
• TT-232: a somatostatin structural derivative as a potent antitumor drug candidate

  2003cites this paper
• Novel sst(4)-selective somatostatin (SRIF) agonists. 4. Three-dimensional consensus structure by NMR.

  2003cites this paper
• Effect of a novel somatostatin analogue combined with cytotoxic drugs on human tumour xenografts and metastasis of B16 melanoma

  2003cites this paper
• The antitumour effect of the somatostatin analogue TT-232 depends on the treatment regimen.

  2003cites this paper
• Novel sst2-selective somatostatin agonists. Three-dimensional consensus structure by NMR.

  2003cites this paper
• TT-232: a somatostatin structural derivative as a potent antitumor drug candidate

  2003cites this paper
• Anti‐inflammatory effect of synthetic somatostatin analogues in the rat

  2001cites this paper
• Synthesis, conformational analysis and bioactivity of Lan‐7, a lanthionine analog of TT‐232

  2000cites this paper
• Apoptosis is induced in both drug-sensitive and multidrug-resistant hepatoma cells by somatostatin analogue TT-232

  1999cites this paper
• A tumor-selective somatostatin analog (TT-232) with strong in vitro and in vivo antitumor activity.

  1996cites this paper
• Conformationally restricted new somatostatin analogs

  1995cites this paper
• Mechanism of action of a tumor-selective somatostatin analog: TT-232

  1995cites this paper